shr-1819
Small moleculeexperimental
Clinical trial activity
11 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started Nov 1, 2020 (NCT04561128)
Timeline
Indications
Mechanism of action
- Interleukin-4 receptor subunit alphaINHIBITOR
IL4R inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07309055 | Phase 3 | Dec 31, 2025 | Hengrui Therapeutics, Inc. |
| NCT07264335 | Phase 1 | Dec 31, 2025 | Hengrui Therapeutics, Inc. |
| NCT07091357 | Phase 2 | Aug 6, 2025 | Hengrui Therapeutics, Inc. |
| NCT06713499 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2024 | Hengrui Therapeutics, Inc. |
| NCT06554509 | Phase 2/Phase 3 (Phase 3) | Sep 19, 2024 | Hengrui Therapeutics, Inc. |
| NCT06468956 | Phase 3 | Jun 30, 2024 | Hengrui Therapeutics, Inc. |
| NCT06012812 | Phase 2 | Sep 6, 2023 | Hengrui Therapeutics, Inc. |
| NCT05549947 | Phase 2 | Oct 12, 2022 | Hengrui Therapeutics, Inc. |
| NCT05197023 | Phase 1 | Jan 31, 2022 | Hengrui Therapeutics, Inc. |
| NCT04772365 | Phase 1 | Mar 1, 2021 | Hengrui Therapeutics, Inc. |
| NCT04561128 | Phase 1 | Nov 1, 2020 | Atridia Pty Ltd. |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 10 | 10 | 3 | 2021 |
| Atridia Pty Ltd. | For profit | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1